Introduction {#sec1_1}
============

In more than 50% of all patients with acute ischemic stroke, high-sensitive cardiac troponin (hs-cTn) is above the cutoff to rule out myocardial infarction \[[@B1]\]. The recently published prospective observational TRoponin ELevation in Acute ischemic Stroke (TRELAS) study revealed that patients with acute ischemic stroke and elevated hs-cTnT were significantly less likely to have coronary culprit lesions than age- and gender-matched patients with non-ST-elevation acute coronary syndrome \[[@B2]\]. Overall, about 25% of all TRELAS patients had a coronary culprit lesion, whereas about 50% did not have any obstructive coronary artery disease (CAD). While conventional coronary angiography is the gold standard to detect CAD, the required periprocedural application of heparin -- increasing the risk of hemorrhagic transformation -- exposure to radiation, procedure-related complications as well as the needed dual antiplatelet therapy after coronary intervention limit the feasibility in the acute phase of ischemic stroke. While noninvasive cardiac computed tomography could add information about underlying CAD \[[@B3]\], the disadvantage of exposure to radiation is also present. Subsequently, assessment of an underlying CAD is often incomplete in patients with acute ischemic stroke in clinical practice. Cardiac magnetic resonance imaging (MRI) is now considered the gold standard to assess cardiac tumors, myocarditis, cardiomyopathies, and subclinical coronary heart disease \[[@B4]\]. Feasibility and safety of noninvasive cardiac MRI in patients with acute ischemic stroke has already been demonstrated. However, routine use of cardiac MRI is limited due to the necessity to follow breath-hold instructions and by the restricted availability of cardiac MRI \[[@B5]\]. This study aimed at comparing the diagnostic value of cardiac MRI compared to coronary angiography in patients with acute ischemic stroke and elevated hs-cTn.

Materials and Methods {#sec1_2}
=====================

The design of the investigator-initiated, prospective observational TRELAS study was published previously \[[@B2], [@B6]\]. The review board of the Charité approved the TRELAS study protocol and the prospective MRI sub-study. All subsequent TRELAS patients at the Charité were asked to join the sub-study. After providing written informed consent, 24 patients admitted within 72 h after stroke onset and in-hospital hs-cTnT \>50 ng/L (Roche, Mannheim, Germany) underwent diagnostic coronary angiography. Patients with creatinine ≥1.2 mg/dL, modified Rankin scale ≥4 before admission, or ST-elevation at baseline echocardiography (ECG) were not enrolled. Nine stroke patients provided informed consent to undergo cardiac MRI at 3T (Magnetom Tim Trio; Siemens AG, Erlangen, Germany) as described previously \[[@B5]\]. ECG-gated images were acquired during breath hold using a phased array receiver coil (Body Matrix-coil\#TATS; Siemens AG). Cine images of three long-axis as well as 14--18 short-axis views using an ECG-gated gradient-echo sequence were acquired. Approximately 10 min after intravenous administration of 0.15 mmol/kg bodyweight Gadobutrol (Gadovist®; Bayer HealthCare, Leverkusen, Germany) at a concentration of 1 mmol/mL, an inversion recovery gradient-echo sequence was acquired in corresponding long-axis and short-axis slices adjusting the inversion time to null normal myocardium. Blinded cardiac MRI reading was done by a board-certified cardiologist (C.J.) specialized in cardiac MRI. Data were summarized with absolute and relative frequencies of qualitative characteristics or medians and interquartile range (IQR) for quantitative variables.

Results {#sec1_3}
=======

The median age of the 9 stroke patients undergoing cardiac MRI was 73 years (range 58--87), four were female. The median NIH Stroke Severity (NIHSS) score on admission was 4 (range 0--6), 3 patients had a history of CAD (Table [1](#T1){ref-type="table"}). Additional information can be found in Table [2](#T2){ref-type="table"}, also including data of the 15 TRELAS patients who either rejected or were unable to undergo cardiac MRI. Besides a higher median creatine kinase on admission in patients undergoing additional MRI, univariate analysis revealed no differences between both patient groups.

All 9 stroke patients completed the cardiac MRI as well as coronary angiography during the in-hospital stay. The median delay between hospital admission and cardiac MRI or coronary angiography was 83 h (IQR 68--106) or 71 h (IQR 45--89), respectively. In 5 stroke patients, combined analysis of wall motion and late gadolinium enhancement showed no substantial findings (Table [3](#T3){ref-type="table"}). Correspondingly, no significant (\>70%) coronary artery stenosis was detected by coronary angiography. Four stroke patients had abnormal MRI findings, whereof 2 patients showed evidence of myocardial infarction. In both patients, coronary angiography demonstrated pathological findings, including a \>70% stenosis of a corresponding coronary artery requiring stenting. Apical ballooning (stress cardiomyopathy) and a reduced cardiac ejection fraction was found in a single stroke patient by both imaging modalities. One patient showed nonischemic late gadolinium enhancement pathognomonic for hypertrophic cardiomyopathy (Table [3](#T3){ref-type="table"}).

Discussion {#sec1_4}
==========

This is the first prospective evaluation comparing the diagnostic value of 3-T cardiac MRI to coronary angiography in acute ischemic stroke patients with elevated hs-cTn. The exclusion of significant CAD by coronary angiography corresponded well with the absence of pathological MRI findings. Therefore, the assumption that cardiac MRI may help identify patients with or without need of invasive evaluation for CAD in the acute phase of ischemic stroke should be validated in a larger prospective study.

By providing information on myocardial infarction, cardiac MRI also appears to have a complementary diagnostic value to past medical history, laboratory results, echocardiography, and ECG parameters in the assessment of acute coronary syndrome in stroke patients. However, cardiac MRI requires active patient cooperation, which cannot always be achieved in the acute phase of stroke \[[@B5]\] (Table [2](#T2){ref-type="table"}).
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###### 

Baseline characteristics, stroke localization, troponin levels (hs-cTnT), and ECG findings in 9 stroke patients of the TRELAS sub-study

  Sex   Age, years   Stroke localization   NIHSS admission   Cardiovascular risk factors   Known CAD   hs-cTnT admission   hs-cTnT follow-up   Pathological ECG findings on admission
  ----- ------------ --------------------- ----------------- ----------------------------- ----------- ------------------- ------------------- ----------------------------------------
  M     71           multiple arteries     0                 AHT, HC, smoking              no          66 ng/L             60 ng/L             none
  F     82           multiple arteries     5                 AF, AHT, HC                   no          13 ng/L             535 ng/L            signs of ischemia
  F     71           PCA left              2                 AF, AHT, HC                   no          510 ng/L            520 ng/L            AF
  M     87           MCA/PCA right         4                 AF, AHT, HC                   yes         20 ng/L             76 ng/L             AF, signs of ischemia
  M     73           MCA/ACA left          6                 AHT                           no          74 ng/L             69 ng/L             none
  F     75           BA                    3                 AHT, HC                       no          95 ng/L             128 ng/L            none
  M     58           multiple arteries     4                 AF, AHT, HCM                  no          144 ng/L            146 ng/L            signs of ischemia, LV hypertrophy
  M     69           MCA left              4                 smoking                       yes         61 ng/L             34 ng/L             LSB
  F     79           multiple arteries     1                 AF, AHT, HC, diabetes         no          347 ng/L            518 ng/L            none

AHT, arterial hypertension; HC, hypercholesterolemia; AF, atrial fibrillation; HCM, hypertrophic cardiomyopathy; LV, left ventricular; LSB, least significant bit; PCA, posterior cerebral artery; MCA, middle cerebral artery; ACA, anterior cerebral artery; BA, basilar artery.

###### 

Baseline characteristics of TRELAS patients with or without cardiac MRI (adapted from \[[@B2]\])

                                           Cardiac MRI (*n* = 9)   No cardiac MRI *(n* = 15)   *P*
  ---------------------------------------- ----------------------- --------------------------- -------
  Median age (IQR), years                  73 (70--81)             77 (64--82)                 0.770
  Male sex                                 55.6 (5)                60.0 (9)                    1.0
  Median NIHSS score (IQR)                 3 (2--4)                3 (3--4)                    0.411
  Median GRACE score (IQR)                 118 (98--145)           113 (83--148)               0.770
  Cardiovascular risk factors                                                                  
   Diabetes mellitus                       22.2 (2)                26.7 (4)                    1.0
   Hypercholesterolemia                    77.8 (7)                46.7 (7)                    0.210
   Hypertension                            100 (9)                 86.7 (13)                   0.511
   Previous stroke                         33.3 (3)                13.3 (2)                    0.326
   Current smoking                         22.2 (2)                13.2 (2)                    0.615
   Atrial fibrillation                     55.6 (5)                46.7 (7)                    1.0
   Chronic heart failure                   22.2 (2)                26.7 (4)                    1.0
   History of CAD                          22.2 (2)                20.0 (3)                    1.0
  Laboratory measures at baseline                                                              
   Median hs-cTn levels (IQR), ng/L        74 (41--247)            85 (44--167)                1.0
   Median creatinine kinase (IQR), mg/dL   166 (117--1540)         86 (61--147)                0.025
   Median creatinine (IQR), mg/dL          1.03 (0.79--1.12)       0.97 (0.88--1.12)           0.907
   Median GFR (IQR), mL/min/1.73 m^2^      72 (63--76)             71 (59--85)                 0.907
  Killip class                                                                                 0.172
   1                                       88.9 (8)                80.0 (12)                   
   2                                       0 (0)                   20.0 (3)                    
   3                                       11.1 (1)                0 (0)                       
  Medication before admission                                                                  
   Prior antiplatelet use                  44.4 (4)                53.3 (8)                    1.0
   Prior oral anticoagulation              11.1 (1)                6.7 (1)                     1.0
   Prior statin use                        44.4 (4)                20.0 (3)                    0.356
   Prior use of beta-blockers              33.3 (3)                38.5 (5)                    1.0

Values are presented as % (n), unless otherwise indicated. GRACE, Global Registry of Acute Coronary Events; GFR, glomerular filtration rate estimated according to the CKD-EPI formula.

###### 

Imaging findings in 9 stroke patients undergoing cardiac MRI and coronary angiography (CA)

  Sex   Age, years   Cardiac MRI - pathological findings (segments)                     Cardiac MRI WMA                                                      MRI EF             Cardiac MRI - late gadolinium enhancement                                          CA - pathological findings (culprit lesion: yes/no)             LVA WMA    LVA EF             Echo -- pathological findings
  ----- ------------ ------------------------------------------------------------------ -------------------------------------------------------------------- ------------------ ---------------------------------------------------------------------------------- --------------------------------------------------------------- ---------- ------------------ -------------------------------
  M     71           none                                                               none                                                                 normal             no                                                                                 none (no)                                                       none       normal             none
                                                                                                                                                                                                                                                                                                                                                                 
  F     82           stress CM                                                          apical ballooning                                                    reduced            no                                                                                 stable lesions in RIVA and RCX \~70% stenosis (no)              apical     severely reduced   EF reduced
                                                                                                                                                                                                                                                                                                                                                                 
  F     71           none                                                               none                                                                 normal             no                                                                                 none (no)                                                       none       normal             \-
                                                                                                                                                                                                                                                                                                                                                                 
  M     87           ischemic CM, hypokinesis and thinned wall (5, 7, 12, 13, 16, 17)   anterior mid-ventricular, apical (RIVA), basal inferolateral (RCX)   severely reduced   transmural anterior mid-ventricular and apical (RIVA), basal inferolateral (RCX)   stable lesions RIVA and RCX \~80% stenosis, CTO RCA; BG (yes)   global     severely reduced   
                                                                                                                                                                                                                                                                                                                                                                 
  M     73           none                                                               none                                                                 normal             no                                                                                 stable peripheral lesion RCX \~50% stenosis (no)                none       normal             none
                                                                                                                                                                                                                                                                                                                                                                 
  F     75           none                                                               none                                                                 normal             no                                                                                 stable lesion RCA \~50% stenosis (no)                           none       normal             −
                                                                                                                                                                                                                                                                                                                                                                 
  M     58           HCM                                                                none                                                                 normal             nonischemic                                                                        none (no)                                                       none       normal             HCM
                                                                                                                                                                                                                                                                                                                                                                 
  M     69           none                                                               none                                                                 normal             no                                                                                 RIVA and RCA stents (no)                                        none       normal             none
                                                                                                                                                                                                                                                                                                                                                                 
  F     79           ischemic CM, hypokinesis and thinned wall (7, 8, 13, 14)           anterior and anterolateral (RIVA)                                    reduced            transmural mid-ventricular to apical anterior and anterolateral                    CTO in RCA, RCX with \~80% stenosis (yes)                       anterior   reduced            none

WMA, wall motion abnormalities; EF, ejection fraction: severely reduced \<40%, reduced 40--65%, normal \>65%; LAV, left ventricular angiography; CM, cardiomyopathy; HCM, hypertrophic cardiomyopathy; RIVA, ramus interventricuaris anterior; RCX, ramus circumflexus; RCA, right coronary artery; CTO, chronic total occlusion; BG, bypass graft.
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